Data from the Phase I/II TRANSCEND CLL 004 study evaluating the combination of Bristol Myers Squibb’s (BMS’s) Breyanzi ...

Most sickle cell disease patients who received the gene-editing therapy Casgevy have been free from vaso-occlusive crises for ...

For patients with newly diagnosed, standard-risk B-cell acute lymphoblastic leukemia (ALL) with an average or high r ...

Long-term exposure to air pollution poses an increased risk of blood clots in deep veins, which can result in serious ...

Notably, at the recently concluded 66th Annual Meeting of the American Society of Hematology (ASH), researchers from Penn ...

Research at the annual meeting of the American Society of Hematology evaluated patient and caregiver perspectives on gene ...

I just returned from San Diego and the annual meeting of the American Society of Hematology, where Arcellx won the battle of ...

In a report released on December 10, Mitchell Kapoor from H.C. Wainwright maintained a Buy rating on Metagenomi, Inc. (MGX – Research Report), ...

according to new Phase II data presented at the American Society of Hematology's annual conference on Monday. Ciara Freeman, ...

When a room of physicians at ASH 2024 was asked whether they had prescribed a gene therapy in a commercial context, only a ...

Wells Fargo has downgraded Editas (EDIT) to equal weight, citing concerns about the potential positioning of reni-cel. Read ...

Adverse events associated with ponatinib in CML and ALL were shown to have decreased significantly since its approval, ...